The Skin Cancer Program is a leading innovator in the research and
treatment of skin cancer, including melanoma, basal cell carcinoma,
squamous cell carcinoma, Merkel cell carcinoma, and cutaneous
lymphoma. Through ongoing research and development, our team is
improving the diagnosis of skin cancer and advancing the field of
Skin Cancer Program
300 Pasteur Drive
Stanford, CA 94305
Maps & Directions
300 Pasteur Drive
Stanford, CA 94305
Getting Here »
Care and Treatment of Skin Cancer
Pigmented Lesion and Melanoma Expertise
Cutaneous melanoma patients and individuals with atypical nevi
(moles) are primarily managed in the Pigmented Lesion and Melanoma
Clinic. This clinic was developed to follow patients at increased risk
of melanoma based on mole pattern and family history as well as to
provide initial evaluation and ongoing surveillance for patients with
cutaneous (skin) and more advanced melanoma.
Patients with atypical mole syndrome are described as having
over 50 to 100 moles with generally 5 or more showing clinical atypia
(variation in color or irregular, asymmetric borders, and/or size
greater than 8mm diameter). Affected individuals are estimated to have
a 5-50-fold increased risk of melanoma depending on family history of melanoma.
The Stanford Pigmented Lesion and Melanoma Clinic employs total body
mole mapping through DigitalDerm™ to assist in the early
detection of severely atypical moles and cutaneous melanoma. Most skin
melanomas do not arise from a pre-existing mole, which adds to the
advantage of total body photography for assessing new or changing
pigmented lesions. Mole mapping is generally recommended for
appropriate patients on a one-time basis, and individuals are
encouraged to use the photos to assist with regular skin
self-examinations. Stanford Dermatology is the sole provider of
Digital Derm total body mole mapping in the San Francisco Bay Area.
Stanford is a participant in the National Cancer
Institute/University of Arizona Phase I/II Cancer Chemoprevention
Consortium, designed to prevent melanoma and other skin cancers in
high-risk individuals at the outset.
Among the specialized treatments available to program patients are:
State-of-art total body digital mole mapping for early
detection of melanoma. A combined PET/CT scanner creates a fusion
of diagnostic capabilities to deliver the most accurate and
sensitive detection of melanoma possible.
lymph node biopsy (SLN) examines the regional lymph nodes for
possible microscopic spread of melanoma. This advanced procedure
sequentially combines preoperative lymphoscintigraphy and
intraoperative mapping to provide a highly accurate means of
identifying the sentinel lymph in malignant melanoma. Use of a novel
gamma camera device to improve accurate SLN identification is
underway through a collaboration between our melanoma surgeons and
the Molecular Imaging Program at Stanford.
Positron emission tomography (PET) is used to detect melanoma
within the body as part of the staging work up. PET scanners do not
use standard radiation, and reveal collections of melanoma cells in
the body that may otherwise be clinically or radiologically
undetectable. Stanford physicians were among the first in the
nation to explore the use of PET for detection of metastatic disease
in melanoma patients and routinely use the combined PET-computed
tomography (CT) scanners for the most accurate staging and
surveillance of patients with melanoma and other cancers.
CyberKnife, a stereotactic radiosurgery technology developed
by Stanford Neurosurgery almost 20 years ago is available for
treatment of brain metastases.
Immunotherapies, including ipilimumab and adjuvant high-dose
interferon for metastatic melanoma patients
Novel chemoprevention trials to prevent the development of
skin cancer (both melanoma and nonmelanoma types) in high-risk
Youn H Kim, MD, Director of Stanford's Cutaneous Lymphoma program on her passion for her profession as a dermatologic oncologist.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Please fax the Medical Record Release Form to your new patient
coordinator. The medical release form is an authorization form for
external facilities to release medical records to Stanford Health Care
(formerly Stanford Hospital & Clinics).
Stanford Health Care (formerly Stanford Hospital & Clinics)
provides comprehensive services to refer and track patients, as well
as provides the latest information and news for physicians and office
staff. For help with all referral needs and questions visit Referring Physicians.
HOW TO REFER
Fax a referral form with supporting documentation to 650-320-9443.
Please note, though this form is from Stanford Health Care (formerly
Stanford Hospital & Clinics), it is also used for all Cancer
Track your patients' progress and communicate with Stanford providers